A Randomized, Double-Blind, Placebo-Controlled, Crossover Study of Xp13512/Gsk1838262 in the Treatment of Patients With Primary Restless Legs Syndrome | Zendy

Clete A. Kushida | Zendy; Arthur S. Walters | Zendy; Philip M. Becker | Zendy; Stephen Thein | Zendy; Amanda Perkins | Zendy; Thomas Roth | Zendy; Daniel M. Canafax | Zendy; Ronald W. Barrett | Zendy

Open Access

A Randomized, Double-Blind, Placebo-Controlled, Crossover Study of Xp13512/Gsk1838262 in the Treatment of Patients With Primary Restless Legs Syndrome

Author(s) -

Clete A. Kushida,

Arthur S. Walters,

Philip M. Becker,

Stephen Thein,

Amanda Perkins,

Thomas Roth,

Daniel M. Canafax,

Ronald W. Barrett

Publication year - 2009

Publication title -

sleep

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.222

H-Index - 207

eISSN - 1550-9109

pISSN - 0161-8105

DOI - 10.1093/sleep/32.2.159

Subject(s) - restless legs syndrome , crossover study , medicine , placebo , double blind , randomized controlled trial , physical therapy , pediatrics , psychology , psychiatry , insomnia , alternative medicine , pathology

To evaluate the efficacy and tolerability of XP13512/ GSK1838262, an investigational nondopaminergic agent for the treatment of moderate-to-severe primary restless legs syndrome (RLS).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research